Safety and Immune Response Study of Shigella Flexneri 2a Vaccine with and without DmLT Adjuvant in Healthy Adults in the Netherlands and Zambia
Led by Leiden University Medical Center · Updated on 2024-11-07
85
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a new injectable Shigella vaccine called InvaplexAR-Detox, combined with a new adjuvant dmLT, in healthy adults aged 18 to 50 years. The study aims to assess whether the vaccine, with or without the adjuvant, is safe, well tolerated, and able to stimulate the immune system effectively. This phase Iab trial involves healthy volunteers from the Netherlands and Zambia and addresses the challenge of improving immune responses to Shigella vaccines, especially in populations susceptible to this infection.
Participants will receive three intramuscular vaccinations spaced 28 days apart. The study includes different groups receiving either low 2.5 g or high 10 g doses of the vaccine, with or without 0.1 g of the dmLT adjuvant, or a placebo saline. The trial begins with the lower dose in the Netherlands, progressing to higher doses after safety reviews. Similar dosing is also given to Zambian participants, allowing comparison across doses and locations.
During the study, participants will undergo regular safety monitoring for adverse events within days following each vaccination. Researchers will also measure immune responses by testing blood samples for antibodies and cellular immune activity at multiple time points up to about 7 months after the first dose. Participants must complete all study visits and procedures, which include stool testing for Shigella and pregnancy testing for women of childbearing potential. The study is designed to carefully track safety and immune responses to better understand the vaccines potential.
CONDITIONS
Brief Title
InvaplexAR-Detox and DmLT Adjuvant in the Netherlands and Zambia
Research Team
M
Meta Roestenberg, MD, PhD
M
Maxim Bax, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Healthy adults aged 18 to 50 years at the time of vaccination
Able to provide written informed consent before starting study procedures
Available to complete all study visits and procedures
Negative stool PCR test for Shigella
Women of childbearing potential must have a negative pregnancy test at screening and before each vaccination
Women of childbearing potential must agree to use continuous adequate contraception from 4 weeks before the first vaccination until 3 months after the last dose
Acceptable contraception methods include hormonal contraception, intrauterine devices or systems, bilateral tubal occlusion, vasectomized partner, or sexual abstinence
You will not qualify if you...
History or evidence of clinically relevant chronic medical conditions such as psychiatric conditions, diabetes, hypertension treated by medication, autoimmune disorders, immunodeficiencies, cardiovascular or renal disease, or inflammatory bowel disease
Current use of immunosuppressive medications except antihistamines and topical or inhalation corticosteroids
Women who are nursing, pregnant, or planning pregnancy during the study and 3 months after the last dose
Participation in research with another investigational product within 30 days before the first vaccination or during the study
Positive blood tests for hepatitis B, hepatitis C, or HIV
Significant abnormalities in basic laboratory screening tests
Systemic antimicrobial treatment within 1 week before the first vaccine dose
Known hypersensitivity or allergy to vaccine or adjuvant components
Regular use of antidiarrheal, anti-constipation, or antacid therapy
Abnormal stool patterns on a regular basis
Personal or family history of inflammatory arthritis
History of anaphylactic reaction to any vaccine
Skin disease that may interfere with assessment or increase risk of local adverse events
Recent gastroenteritis within 3 months
Previous receipt of licensed or experimental Shigella vaccine, dmLT, or live Shigella challenge
Any severe medical condition increasing risk of adverse events by clinical judgment
Planned vaccinations within 14 days before first vaccine dose until last study visit, except SARS-CoV-2 or influenza vaccines
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Approximately 8 weeks
Participants receive three intramuscular vaccinations of the candidate Shigella vaccine with or without adjuvant at 28-day intervals.
3 vaccination visits spaced 4 weeks apart
Follow-up
Duration - Approximately 6 months
Participants are monitored for safety and immune response after the last vaccination.
Follow-up visits on study days 64, 85, and 225
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
FACTORIAL
Primary Purpose
PREVENTION
Number of Arms
5
Similar Trials
Safety and Immune Response Study of Shigella Flexneri 2a Vaccine with and without DmLT Adjuvant in Healthy Adults in the Netherlands and Zambia
Study to Find and Confirm Safe Dose of Shigella sonnei 53G Infection in Healthy Kenyan Adults Aged 18 to 45
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Safety, Tolerability, and Immunogenicity of the InvaplexAR-DetoxShigella Vaccine Co-Administered with the dmLT Adjuvant in Dutch and Zambian Adults: Study Protocol for a Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase Ia/b Clinical Trial.